InstalabLoading...
InstalabLoading...
Almost every adult walking around today carries human herpesvirus 6 (HHV-6) in their body. You probably picked it up before your second birthday, when it may have caused roseola, that brief fever-and-rash illness that most parents barely remember. After that initial infection, the virus never fully leaves. It tucks itself into your immune cells and stays dormant, sometimes for decades. For most people, this is completely harmless. But for some, particularly when the immune system is weakened or stressed, the virus can reactivate and cause real problems.
HHV-6 IgG (immunoglobulin G) is an antibody your body produces in response to this virus. A positive result tells you that your immune system has encountered HHV-6 at some point. On its own, a single positive reading does not tell you whether the virus is active right now or whether it quietly infected you 30 years ago. That distinction is where careful interpretation, and sometimes additional testing, becomes essential.
After your body first fights off HHV-6, a type of white blood cell called a plasma cell begins producing IgG antibodies targeted specifically at this virus. Unlike IgM antibodies, which spike during the initial infection and fade within weeks, IgG antibodies persist for life. They serve as your immune system's long-term memory of the encounter. When you get this blood test, you are measuring the concentration of these memory antibodies circulating in your blood.
Because 80 to 95% of adults test positive for HHV-6 IgG, a single positive result is expected and is not a cause for concern on its own. The clinical value comes from watching the trend. A fourfold rise in antibody levels between two blood draws taken several weeks apart suggests the virus may be waking up and actively replicating. That pattern, not a single snapshot, is what makes this test medically meaningful.
In people with healthy immune systems, HHV-6 reactivation is usually silent or causes mild, self-limiting symptoms. The immune system recognizes the familiar virus and suppresses it before it can do damage. But when the immune system is compromised, whether by organ transplant medications, chemotherapy, or severe illness, reactivation can become dangerous.
The most serious complication is encephalitis, a life-threatening inflammation of the brain. In stem cell transplant recipients, HHV-6 encephalitis occurs in a meaningful fraction of patients, and studies show that combination antiviral therapy reduced death or lasting neurological damage to about 38% compared to roughly 56 to 64% with single-drug treatment. The virus can also affect the liver, lungs, bone marrow, and gastrointestinal tract in immunosuppressed individuals.
Outside the transplant setting, HHV-6 has drawn attention as a possible contributor to chronic fatigue and other persistent, hard-to-diagnose conditions. Some clinicians have observed elevated HHV-6 IgG titers in patients with prolonged fatigue, brain fog, and neurological symptoms. One small open-label study treated patients who had elevated HHV-6 antibody titers along with central nervous system dysfunction and long-standing fatigue with six months of antiviral medication and observed a decrease in titers, though the change was not statistically significant and the study lacked a control group.
This area of research remains preliminary. If you are experiencing unexplained fatigue or cognitive symptoms and standard workups have come back normal, checking your HHV-6 IgG level and then retesting several weeks later can at least tell you whether your antibody levels are rising, which would suggest active viral replication worth investigating further.
HHV-6 actually comes in two variants: HHV-6A and HHV-6B. HHV-6B is the one responsible for nearly all childhood roseola infections and most adult reactivation events. HHV-6A is less common and its clinical role is less well defined. Most commercial antibody tests do not distinguish between the two variants. Your result reflects combined exposure to both.
HHV-6 IgG results are typically reported as either positive or negative, or as a titer (a measure of antibody concentration expressed as a ratio like 1:10 or 1:320). There are no universally standardized clinical cutpoints for this test. Different labs use different assay platforms with their own thresholds for calling a result positive.
| Result | What It Suggests |
|---|---|
| Negative (below lab cutoff) | No detected antibodies to HHV-6. Either you have never been exposed (uncommon in adults) or your immune system is not producing measurable antibodies. |
| Positive (above lab cutoff) | Your immune system has encountered HHV-6 at some point. This is the expected result for most adults and does not indicate active infection on its own. |
| Fourfold titer rise on paired samples | Suggests recent infection or viral reactivation. This is the most clinically meaningful pattern and warrants further investigation. |
Because the cutoff for a positive result varies by lab and assay method, always compare your results within the same laboratory over time rather than treating any single threshold as absolute.
Antibody levels are not static across your lifetime. Newborns carry their mother's HHV-6 antibodies, which decline over the first six months. Primary infection typically occurs between 6 months and 2 years of age, and antibody levels peak shortly after. In adults over 50, studies have found that seroprevalence actually drops to 35 to 70%, and antibody titers tend to be lower, possibly because viral reactivation becomes less frequent with aging.
Geographic variation also exists. Studies across different regions show adult seroprevalence ranging from 20% in Morocco to over 90% in parts of sub-Saharan Africa and South America, with antibody concentrations varying substantially. These population-level differences do not change how you interpret your own trend, but they do explain why your result might differ from a friend or family member in another part of the world.
The single biggest source of confusion with this test is assuming a positive result means active infection. It almost never does. A positive HHV-6 IgG simply means you were exposed at some point, which is true for the vast majority of adults. Only a fourfold rise in titers between paired blood draws reliably suggests reactivation.
Other herpesvirus infections can temporarily inflate your HHV-6 IgG reading. When the Epstein-Barr virus (the virus behind mononucleosis) becomes active, it can trigger a broad burst of antibody production that transiently raises HHV-6 IgG levels. This is not because HHV-6 itself has reactivated. It is a bystander effect of generalized immune stimulation, driven by the widespread activation of antibody-producing cells during mononucleosis. Cytomegalovirus (CMV) infection can do the same thing.
Immunosuppressive medications create a different kind of interpretive challenge. Corticosteroids and other drugs that suppress the immune system can both trigger viral reactivation (raising antibody levels) and impair antibody production (lowering them). In transplant recipients, antibody levels often drop sharply in the first few months after transplant, which can make it look like the virus is under control when it may actually be reactivating without a strong antibody response to flag it.
At very low antibody concentrations (titers below 1:32), some cross-reactivity with HHV-7, a closely related virus, can occur. Modern commercial assays generally have good specificity, but borderline-low positive results should be interpreted cautiously.
About 1% of the population carries HHV-6 DNA woven directly into their chromosomes, a condition called chromosomally integrated HHV-6 (ciHHV-6). This is inherited and present in every cell of the body. It primarily confounds DNA-based tests (PCR) rather than antibody tests, but it is worth knowing about if you are pursuing additional workup. If a PCR test shows a very high viral DNA load but your antibody levels are stable, ciHHV-6 may be the explanation rather than active infection.
A single HHV-6 IgG reading tells you almost nothing actionable. The power of this test lies in serial measurement. If you are investigating whether HHV-6 reactivation might be contributing to symptoms, the recommended approach is to draw an initial blood sample during the symptomatic period and a second sample two to four weeks later. Both samples should be tested at the same laboratory, ideally run side by side in the same assay batch, to minimize technical variation between runs.
A fourfold rise in titer between the two draws is the established threshold for suggesting recent infection or reactivation. Smaller changes could reflect normal lab variability. No published data exists on the natural fluctuation (intra-individual coefficient of variation) of HHV-6 IgG in healthy adults, which makes it even more important to use the fourfold-rise standard rather than reading too much into modest shifts.
If you are using this test as part of a broader immune surveillance strategy, an annual baseline is reasonable. If you are actively investigating symptoms or monitoring after an intervention, retest in 4 to 6 weeks to see whether your titer is moving in a meaningful direction.
HHV-6 IgG is best interpreted alongside these tests.